A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of PD-L1 inhibitorin in
combination with Anlotinib treatment for patients with triple receptor negative breast cancer
treated after failure of standard therapy (including Anthracyclines and/or Taxanes).